Korean Circ J.  2022 Apr;52(4):320-323. 10.4070/kcj.2022.0022.

Unguided De-Escalation Strategy From Potent P2Y ₁₂ Inhibitors in Patients Presented With ACS: When, Whom and How?

• Park JS
• Jeong YH

• KMID: 2528026
• DOI: http://doi.org/10.4070/kcj.2022.0022

Abstract

no abstract available.

Figure

• 

  Figure 1 Patient-tailored antithrombotic strategies in patients with acute coronary syndrome (modified from van der Sangen et al.)5) - 7) DAPT = dual antiplatelet therapy; FXa = factor Xa.

• 

  Figure 2 The MASTER-DAPT trial: net clinical benefit of abbreviated vs. stardard DAPT in patients with an OAC indication (left) and without an OAC indication (right).BARC = Bleeding Academic Research Consortium; DAPT = dual antiplatelet therapy; MASTER-DAPT = Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Standard DAPT Regimen; MI = myocardial infarction; NNH = number needed to harm; NNT = number needed to treat; OAC = oral anticoagulant.

Reference

1. Collet JP, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021; 42:1289–1367. PMID: 32860058.

2. Kupka D, Sibbing D. De-escalation of P2Y12 receptor inhibitor therapy after acute coronary syndromes in patients undergoing percutaneous coronary intervention. Korean Circ J. 2018; 48:863–872. PMID: 30238704.

3. Tavenier AH, Mehran R, Chiarito M, et al. Guided and unguided de-escalation from potent P2Y12 inhibitors among patients with ACS: a meta-analysis. Eur Heart J Cardiovasc Pharmacother. 2021; pvab068. PMID: 34459481.

4. Ki YJ, Lee BK, Park KW, et al. Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with STEMI. Korean Circ J. 2022; 52:304–319. PMID: 35129316.

5. van der Sangen NMR, Rozemeijer R, Chan Pin Yin DRPP, et al. Patient-tailored antithrombotic therapy following percutaneous coronary intervention. Eur Heart J. 2021; 42:1038–1046. PMID: 33515031.

6. Smits PC, Frigoli E, Tijssen J, et al. Abbreviated antiplatelet therapy in patients at high bleeding risk with or without oral anticoagulant therapy after coronary stenting: an open-label, randomized, controlled trial. Circulation. 2021; 144:1196–1211. PMID: 34455849.

7. Watanabe H. STOPDAPT-2 ACS: one-month dual antiplatelet therapy followed by clopidogrel monotherapy in acute coronary syndrome. In : ESC Congress; 2021 Aug 27-30.

8. Kim HK, Tantry US, Park HW, et al. Ethnic difference of thrombogenicity in patients with cardiovascular disease: a pandora box to explain prognostic differences. Korean Circ J. 2021; 51:202–221. PMID: 33655720.

9. Jeong YH, Oh JH, Yoon HJ, et al. Pharmacodynamic profile and prevalence of bleeding episode in East Asian patients with acute coronary syndromes treated with prasugrel standard-dose versus de-escalation strategy: a randomized A-MATCH trial. Thromb Haemost. 2021; 121:1376–1386. PMID: 33401330.

10. Lee SH, Kim HK, Jeong MH, et al. Practical guidance for P2Y12 inhibitors in acute myocardial infarction undergoing percutaneous coronary intervention. Eur Heart J Cardiovasc Pharmacother. 2021; 7:112–124. PMID: 31977008.